As we have previously reported, Regeneron’s BPCIA case against Mylan regarding Mylan’s proposed aflibercept biosimilar is proceeding on an expedited schedule, with a two-week trial scheduled to begin on June 12, 2023.
On...more
On October 10, 2018, the United States Patent and Trademark Office (PTO) announced a final rule changing the claim construction standard applied during inter partes review (IPR), post-grant review (PGR), and covered business...more